FDA Actions

November 2009
Internal Medicine Alert;Nov2009 Pharmacology Watch Supp, p2
The article reports that the U.S. Food and Drug Administration has approved the use of asenapine for first-line treatment of schizophrenia and bipolar I disorder in adults.


Related Articles

  • Lilly seeks FDA approval for schizophrenia drug.  // Indianapolis Business Journal;9/25/95, Vol. 16 Issue 27, p52A 

    Reports that Eli Lilly & Co. is seeking approval from the Food and Drug Administration to market olanzapine, a drug used to treat schizophrenia and other psychotic disorders. Symptoms of schizophrenia.

  • Dosing and Switching Strategies for Paliperidone Palmitate Based on Population Pharmacokinetic Modelling and Clinical Trial Data. Samtani, Mahesh N.; Gopal, Srihari; Gassmann-Mayer, Cristiana; Alphs, Larry; Palumbo, Joseph M. // CNS Drugs;2011, Vol. 25 Issue 10, p829 

    Paliperidone palmitate is a second-generation, long-acting injectable (LAI) antipsychotic recently approved by the US FDA and European Medicines Agency for use in patients with schizophrenia. This article reviews the re- commended dosing regimens for initiation and maintenance treatment with...

  • FDA Actions. Elliott, William T. // Infectious Disease Alert;Jul2009 Supplement, p2 

    The article reports on the need for two topical testosterone gel products to carry boxed warnings on their labeling following a ruling by the U.S. Food and Drug Administration (FDA) that the gels may cause adverse effects in children who are exposed by contact with adults who are using the...

  • Approvals for Zyprexa.  // Monthly Prescribing Reference;Jan2010, Vol. 26 Issue 1, pA11 

    The article reports on the approval of the drug Zyprexa Relprevv from Lilly as treatment for adults with schizophrenia by the U.S. Food and Drug Administration (FDA).

  • Schizophrenia drug approved but with a name change. Ukens, Carol // Drug Topics;2/19/2001, Vol. 145 Issue 4, p12 

    Reports on the approval of Pfizer's ziprasidone HCl for the treatment of schizophrenia by the United States Food and Drug Administration. Potential heart risks of ziprasidone; Results of the worldwide clinical trials for the drug.

  • Mylan launches generic version of schizophrenia drug.  // PharmaWatch: CNS;Jul2011, Vol. 10 Issue 7, p26 

    The article offers updates on the developments of fully integrated pharmaceutical company Mylan Pharmaceuticals Inc., one on the launch of schizophrenic drug risperidone and the 169 pending approval of its abbreviated new drug applications (ANDAs) by the U.S. Food and Drug Administration (FDA).

  • NEWSLINE: Schizophrenia Tx Allows Quarterly Dosing.  // Monthly Prescribing Reference;Jul2015, Vol. 31 Issue 7, pA8 

    The article reports on the approval of the Invega Trinza (paliperidone palmitate) extended-release injectable suspension by the U.S. Food and Drug Administration (FDA) for schizophrenia treatment in adults that requires administration for only four times a year.

  • Lundbeck's and Otsuka's NDA for schizophrenia drug receives FDA acceptance.  // PharmaWatch: CNS;Nov2012, Vol. 11 Issue 11, p14 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of the resubmission for review of the new drug application (NDA) by Denmark's H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. for their aripiprazole depot formulation aimed at treating schizophrenia.

  • New Schizophrenia Drug.  // FDA Consumer;May/Jun2001, Vol. 35 Issue 3, p6 

    Deals with the drug Geodon or ziprasidone, which was approved by the United States Food and Drug Administration for the treatment of schizophrenia. Characteristics of schizophrenia; Plan of Pfizer Inc. to market the medication under the name Zeldox; Side effects of the drug.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics